NASDAQ:IVA

Inventiva Competitors

$13.27
-0.12 (-0.90 %)
(As of 04/21/2021 03:45 AM ET)
Add
Compare
Today's Range
$13.27
Now: $13.27
$13.27
50-Day Range
$12.55
MA: $13.93
$15.75
52-Week Range
$9.01
Now: $13.27
$19.06
Volume4,442 shs
Average Volume36,086 shs
Market Capitalization$512.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Inventiva (NASDAQ:IVA) Vs. MDGL, MGNX, NGM, AMRN, RVNC, and AXSM

Should you be buying IVA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Inventiva, including Madrigal Pharmaceuticals (MDGL), MacroGenics (MGNX), NGM Biopharmaceuticals (NGM), Amarin (AMRN), Revance Therapeutics (RVNC), and Axsome Therapeutics (AXSM).

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Insider and Institutional Ownership

74.2% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.5% of Inventiva shares are owned by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Madrigal Pharmaceuticals and Inventiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Madrigal PharmaceuticalsN/A-47.64%-43.21%
InventivaN/AN/AN/A

Valuation & Earnings

This table compares Madrigal Pharmaceuticals and Inventiva's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-23.81
InventivaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Madrigal Pharmaceuticals and Inventiva, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Madrigal Pharmaceuticals03702.70
Inventiva11001.50

Madrigal Pharmaceuticals currently has a consensus target price of $167.60, suggesting a potential upside of 29.14%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Madrigal Pharmaceuticals is more favorable than Inventiva.

Summary

Madrigal Pharmaceuticals beats Inventiva on 5 of the 7 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares MacroGenics and Inventiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MacroGenics-204.31%-65.84%-49.41%
InventivaN/AN/AN/A

Insider & Institutional Ownership

95.8% of MacroGenics shares are held by institutional investors. Comparatively, 10.5% of Inventiva shares are held by institutional investors. 9.0% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares MacroGenics and Inventiva's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$64.19 million31.91$-151,810,000.00($3.16)-10.81
InventivaN/AN/AN/AN/AN/A

Inventiva has lower revenue, but higher earnings than MacroGenics.

Analyst Ratings

This is a summary of current recommendations for MacroGenics and Inventiva, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MacroGenics11902.73
Inventiva11001.50

MacroGenics currently has a consensus target price of $33.40, suggesting a potential downside of 2.22%. Given MacroGenics' stronger consensus rating and higher possible upside, research analysts clearly believe MacroGenics is more favorable than Inventiva.

Summary

MacroGenics beats Inventiva on 6 of the 9 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares NGM Biopharmaceuticals and Inventiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
InventivaN/AN/AN/A

Insider and Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 10.5% of Inventiva shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares NGM Biopharmaceuticals and Inventiva's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million19.68$-42,790,000.00($0.85)-31.26
InventivaN/AN/AN/AN/AN/A

Inventiva has lower revenue, but higher earnings than NGM Biopharmaceuticals.

Analyst Recommendations

This is a summary of current ratings for NGM Biopharmaceuticals and Inventiva, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
Inventiva11001.50

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, suggesting a potential upside of 47.03%. Given NGM Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NGM Biopharmaceuticals is more favorable than Inventiva.

Summary

NGM Biopharmaceuticals beats Inventiva on 7 of the 10 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares Amarin and Inventiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarin-2.69%-2.70%-1.72%
InventivaN/AN/AN/A

Valuation and Earnings

This table compares Amarin and Inventiva's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$429.76 million4.61$-22,650,000.00($0.07)-72.00
InventivaN/AN/AN/AN/AN/A

Inventiva has lower revenue, but higher earnings than Amarin.

Insider and Institutional Ownership

37.8% of Amarin shares are owned by institutional investors. Comparatively, 10.5% of Inventiva shares are owned by institutional investors. 2.8% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Amarin and Inventiva, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarin03802.73
Inventiva11001.50

Amarin presently has a consensus target price of $11.1818, suggesting a potential upside of 121.86%. Given Amarin's stronger consensus rating and higher possible upside, analysts clearly believe Amarin is more favorable than Inventiva.

Summary

Amarin beats Inventiva on 6 of the 9 factors compared between the two stocks.

Inventiva (NASDAQ:IVA) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Inventiva and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InventivaN/AN/AN/A
Revance Therapeutics-5,818.87%-85.72%-44.85%

Valuation & Earnings

This table compares Inventiva and Revance Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InventivaN/AN/AN/AN/AN/A
Revance Therapeutics$410,000.004,770.47$-159,430,000.00($3.67)-7.47

Inventiva has higher earnings, but lower revenue than Revance Therapeutics.

Institutional and Insider Ownership

10.5% of Inventiva shares are owned by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are owned by institutional investors. 4.8% of Revance Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Inventiva and Revance Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inventiva11001.50
Revance Therapeutics00403.00

Revance Therapeutics has a consensus price target of $37.75, suggesting a potential upside of 37.77%. Given Revance Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Revance Therapeutics is more favorable than Inventiva.

Summary

Revance Therapeutics beats Inventiva on 6 of the 9 factors compared between the two stocks.

Inventiva (NASDAQ:IVA) and Axsome Therapeutics (NASDAQ:AXSM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Inventiva and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InventivaN/AN/AN/A
Axsome TherapeuticsN/A-62.33%-47.87%

Valuation & Earnings

This table compares Inventiva and Axsome Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InventivaN/AN/AN/AN/AN/A
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.32

Institutional and Insider Ownership

10.5% of Inventiva shares are owned by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Inventiva and Axsome Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inventiva11001.50
Axsome Therapeutics101002.82

Axsome Therapeutics has a consensus price target of $152.6667, suggesting a potential upside of 190.52%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Inventiva.

Summary

Axsome Therapeutics beats Inventiva on 5 of the 7 factors compared between the two stocks.


Inventiva Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.78-2.7%$2.02 billionN/A-11.72News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$34.16-1.5%$2.02 billion$64.19 million-10.91Analyst Report
Insider Selling
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.57-2.9%$1.98 billion$103.54 million-19.98
Amarin logo
AMRN
Amarin
1.6$5.04-1.8%$1.95 billion$429.76 million-100.78
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.40-2.2%$1.91 billion$410,000.00-5.96
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.91-4.3%$1.89 billionN/A-19.67Unusual Options Activity
News Coverage
FibroGen logo
FGEN
FibroGen
1.8$20.23-0.6%$1.87 billion$256.58 million-7.75
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$58.13-0.3%$1.86 billionN/A-24.74
Kura Oncology logo
KURA
Kura Oncology
1.6$27.63-1.2%$1.85 billionN/A-16.95News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.18-0.5%$1.81 billion$26.87 million-13.18Analyst Report
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$19.88-1.4%$1.79 billion$34.51 million-16.99
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18
MORF
Morphic
1.3$57.34-5.4%$1.76 billion$16.98 million-36.76Insider Selling
Gap Up
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.71-0.5%$1.72 billion$428.41 million15.52Analyst Upgrade
Unusual Options Activity
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.69-0.4%$1.70 billion$1.63 billion13.88
Generation Bio logo
GBIO
Generation Bio
1.8$30.48-1.3%$1.70 billionN/A0.00Gap Up
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.80-0.1%$1.63 billion$145.97 million-7.21
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.49-2.5%$1.62 billion$392.76 million13.07Analyst Upgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.90-5.5%$1.62 billionN/A-6.73Analyst Downgrade
Increase in Short Interest
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.24-1.2%$1.58 billion$2.34 million-9.85
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.82-1.4%$1.56 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$35.81-7.2%$1.55 billionN/A0.00Analyst Upgrade
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.58-1.4%$1.52 billion$175.34 million-15.05Insider Selling
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.16-2.4%$1.51 billion$320,000.00-8.27
uniQure logo
QURE
uniQure
1.7$31.89-1.9%$1.46 billion$7.28 million-8.46Unusual Options Activity
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.45-1.7%$1.46 billion$82.27 million-18.17
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$29.48-2.8%$1.44 billionN/A-3.19Analyst Upgrade
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$61.95-1.1%$1.43 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$22.22-0.6%$1.42 billion$73.41 million-4.70News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.59-2.0%$1.40 billionN/A0.00
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.00-2.3%$1.40 billionN/A0.00Gap Down
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.89-0.5%$1.38 billion$6.20 million-13.99
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.02-1.9%$1.37 billion$19.89 million-13.22
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.47-3.7%$1.37 billion$4.23 million-20.35Analyst Report
Increase in Short Interest
News Coverage
Gap Down
OLMA
Olema Pharmaceuticals
1.6$34.92-3.9%$1.35 billionN/A0.00Gap Up
Endo International logo
ENDP
Endo International
1.5$5.75-2.1%$1.30 billion$2.91 billion-8.46
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.57-7.0%$1.28 billionN/A-144.04Analyst Downgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$29.51-0.0%$1.23 billionN/A0.00Analyst Report
Insider Selling
Zymeworks logo
ZYME
Zymeworks
1.8$27.25-2.8%$1.22 billion$29.54 million-7.23News Coverage
Innoviva logo
INVA
Innoviva
1.4$12.03-0.4%$1.21 billion$261.02 million6.14News Coverage
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$32.81-1.6%$1.18 billionN/A0.00Analyst Upgrade
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$31.25-2.2%$1.18 billionN/A0.00Analyst Report
Insider Selling
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$27.59-3.5%$1.17 billion$230,000.00-12.83
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.93-4.6%$1.16 billion$59.70 million-199.30
Omeros logo
OMER
Omeros
1.2$19.12-3.0%$1.15 billion$111.81 million-8.03
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.81-1.1%$1.14 billionN/A-17.12
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.09-0.1%$1.14 billionN/A-8.78Analyst Report
Increase in Short Interest
News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.7$21.07-4.7%$1.13 billionN/A0.00Insider Selling
News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.31-3.5%$1.12 billion$4.23 million-8.55
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.